Skip to content

HALOZYME THERAPEUTICS, INC.

HALO

CIK 0001159036

← back to feed
Revenue (TTM)
$1.32B
+37.6% YoY Q1 Apr 2026
Net Income (TTM)
$608.53M
−28.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
$4.91
−25.4% YoY Q1 Apr 2026
Gross Margin
0.5%
Q1 Apr 2026
Operating Margin
56.5%
Q1 Apr 2026
Net Margin
46.0%
Q1 Apr 2026
Free Cash Flow (TTM)
$531.08M
Q1 Apr 2026
Cash
$309.75M
Q1 Apr 2026
Total Debt
$2.14B
Q1 Apr 2026
Shares Outstanding
118.61M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings